Myriad Genetics (MYGN +3%) finished the day solidly higher on the back of a New York Times op-ed...

|About: Myriad Genetics, Inc. (MYGN)|By:, SA News Editor

Myriad Genetics (MYGN +3%) finished the day solidly higher on the back of a New York Times op-ed piece by Angelina Jolie outlining her decision to have a double mastectomy after learning she had an 87% chance of developing breast cancer. MYGN holds the patent on the test that made the determination, as well as the genes themselves. The test looks for defects in the BRCA1 or BRCA2 genes, which are the cause of most hereditary breast cancer cases.